{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:25:38Z","timestamp":1780997138058,"version":"3.54.1"},"reference-count":71,"publisher":"Harborside Press, LLC","issue":"2D","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Ampullary carcinomas are rare but increasing in incidence. Ampullary cancers have molecular alterations that guide choice of therapy, particularly in nonresectable cases. These alterations can be more common by subtype (intestinal, pancreaticobiliary, or mixed), and next-generation sequencing is recommended for all patients who cannot undergo surgery. In this article, we review the approach to tissue acquisition and consideration for molecular testing. Common molecular targets of interest in ampullary cancer are also discussed in this review, including <jats:italic>HER2\/ERBB2<\/jats:italic>, <jats:italic>HER3<\/jats:italic>, tumor mutational burden, microsatellite instability, <jats:italic>KRAS<\/jats:italic>, and germline <jats:italic>BRCA<\/jats:italic> and <jats:italic>ATM<\/jats:italic> mutations, along with emerging and rarer alterations.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7051","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T19:20:39Z","timestamp":1704482439000},"source":"Crossref","is-referenced-by-count":5,"title":["Molecular Targets and Therapies for Ampullary Cancer"],"prefix":"10.6004","volume":"22","author":[{"given":"Monica Arun","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Kratz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin"},{"name":"University of Wisconsin Center for Human Genomics and Precision Medicine, Madison, Wisconsin"},{"name":"William S. Middleton Memorial Veterans Hospital, Shorewood Hills, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ysaith Orellana","family":"Ascencio","sequence":"additional","affiliation":[{"name":"Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broc S.","family":"Kelley","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle K.","family":"LoConte","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin"},{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Periampullary carcinoma","year":"2001","unstructured":"Fernandez-Cruz L. Periampullary carcinoma. In: Holzheimer RG, Mannick JA, eds. Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt Verlag GmbH; 2001."},{"key":"B2","series-title":"Anat Anz","first-page":"77","article-title":"[Abraham Vater (1684\u20131751)]","volume":"160","author":"Wackwitz W","year":"1985","unstructured":"Wackwitz W. [Abraham Vater (1684\u20131751)]. Anat Anz 1985;160:77\u201379 [in German]."},{"key":"B3","series-title":"Abdom Imaging","first-page":"3274","article-title":"MDCT and MRI of the ampulla of Vater. Part I: technique optimization, normal anatomy, and epithelial neoplasms","volume":"40","author":"Alessandrino F","year":"2015","unstructured":"Alessandrino F, Ivanovic AM, Yee EU,  MDCT and MRI of the ampulla of Vater. Part I: technique optimization, normal anatomy, and epithelial neoplasms. Abdom Imaging 2015;40:3274\u20133291."},{"key":"B4","series-title":"Jpn J Cancer Res","first-page":"161","article-title":"Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater","volume":"85","author":"Kimura W","year":"1994","unstructured":"Kimura W, Futakawa N, Yamagata S,  Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85:161\u2013166."},{"key":"B5","series-title":"Curr Oncol","first-page":"3393","article-title":"Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges","volume":"28","author":"Rizzo A","year":"2021","unstructured":"Rizzo A, Dadduzio V, Lombardi L,  Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges. Curr Oncol 2021;28:3393\u20133402."},{"key":"B6","series-title":"JAMA Surg","first-page":"706","article-title":"Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma","volume":"154","author":"Ecker BL","year":"2019","unstructured":"Ecker BL, Vollmer CM Jr, Behrman SW,  Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg 2019;154:706\u2013714."},{"key":"B7","series-title":"Sci Rep","first-page":"12676","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann C","year":"2019","unstructured":"Zimmermann C, Wolk S, Aust DE,  The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 2019;9:12676."},{"key":"B8","series-title":"J Clin Oncol","first-page":"1348","article-title":"Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater","volume":"31","author":"Chang DK","year":"2013","unstructured":"Chang DK, Jamieson NB, Johns AL,  Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater. J Clin Oncol 2013;31:1348\u20131356."},{"key":"B9","series-title":"Am J Surg Pathol","first-page":"359","article-title":"Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2","volume":"29","author":"Chu PG","year":"2005","unstructured":"Chu PG, Schwarz RE, Lau SK,  Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005;29:359\u2013367."},{"key":"B10","series-title":"Int J Surg Pathol","first-page":"31","article-title":"Differential expression of \u03b2-catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in intestinal and pancreatobiliary-type ampullary carcinomas","volume":"25","author":"Perysinakis I","year":"2017","unstructured":"Perysinakis I, Minaidou E, Leontara V,  Differential expression of \u03b2-catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in intestinal and pancreatobiliary-type ampullary carcinomas. Int J Surg Pathol 2017;25:31\u201340."},{"key":"B11","series-title":"Medicine (Baltimore)","first-page":"e17711","article-title":"Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer","volume":"98","author":"Park HM","year":"2019","unstructured":"Park HM, Park SJ, Han SS,  Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer. Medicine (Baltimore) 2019;98:e17711."},{"key":"B12","series-title":"J Surg Oncol","first-page":"598","article-title":"Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program","volume":"100","author":"Albores-Saavedra J","year":"2009","unstructured":"Albores-Saavedra J, Schwartz AM, Batich K,  Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009;100:598\u2013605."},{"key":"B13","series-title":"Ann Surg Oncol","first-page":"50","article-title":"Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer","volume":"14","author":"Hsu HP","year":"2007","unstructured":"Hsu HP, Yang TM, Hsieh YH,  Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007;14:50\u201360."},{"key":"B14","series-title":"Ann Surg Oncol","first-page":"1176","article-title":"Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater","volume":"10","author":"Todoroki T","year":"2003","unstructured":"Todoroki T, Koike N, Morishita Y,  Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003;10:1176\u20131183."},{"key":"B15","series-title":"Am Soc Clin Oncol Educ Book","first-page":"112","article-title":"Ampullary cancer: an overview","volume":"34","author":"Ahn DH","year":"2014","unstructured":"Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book 2014;34:112\u2013115."},{"key":"B16","series-title":"Cancer Epidemiol","first-page":"e207","article-title":"Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007","volume":"36","author":"Coupland VH","year":"2012","unstructured":"Coupland VH, Kocher HM, Berry DP,  Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007. Cancer Epidemiol 2012;36:e207\u2013214."},{"key":"B17","series-title":"Minerva Gastroenterol Dietol","first-page":"85","article-title":"Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study","volume":"65","author":"Ramai D","year":"2019","unstructured":"Ramai D, Ofosu A, Singh J,  Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study. Minerva Gastroenterol Dietol 2019;65:85\u201390."},{"key":"B18","series-title":"Curr Oncol","first-page":"449","article-title":"Clinicopathological features and prognosis analysis of primary bile duct and ampullary neuroendocrine neoplasms: a population-based study from 1975 to 2016","volume":"30","author":"Li Y","year":"2022","unstructured":"Li Y, Hua R, He J,  Clinicopathological features and prognosis analysis of primary bile duct and ampullary neuroendocrine neoplasms: a population-based study from 1975 to 2016. Curr Oncol 2022;30:449\u2013461."},{"key":"B19","series-title":"Cancer","first-page":"1441","article-title":"Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes","volume":"125","author":"Wong W","year":"2019","unstructured":"Wong W, Lowery MA, Berger MF,  Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019;125:1441\u20131448."},{"key":"B20","series-title":"Orphanet J Rare Dis","first-page":"22","article-title":"Familial adenomatous polyposis","volume":"4","author":"Half E","year":"2009","unstructured":"Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009;4:22."},{"key":"B21","series-title":"Bull Cancer","first-page":"647","article-title":"[Lynch syndrome: what is new?]","volume":"106","author":"Pellat A","year":"2019","unstructured":"Pellat A, Netter J, Perkins G,  [Lynch syndrome: what is new?]. Bull Cancer 2019;106:647\u2013655 [in French]."},{"key":"B22","series-title":"Clin Gastroenterol Hepatol","first-page":"659","article-title":"Features of duodenal cancer in patients with familial adenomatous polyposis","volume":"7","author":"Latchford AR","year":"2009","unstructured":"Latchford AR, Neale KF, Spigelman AD,  Features of duodenal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2009;7:659\u2013663."},{"key":"B23","series-title":"J Med Genet","first-page":"59","article-title":"Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance","volume":"50","author":"Korsse SE","year":"2013","unstructured":"Korsse SE, Harinck F, van Lier MG,  Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 2013;50:59\u201364."},{"key":"B24","series-title":"J Gastrointest Surg","first-page":"1052","article-title":"Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases","volume":"14","author":"Relles D","year":"2010","unstructured":"Relles D, Baek J, Witkiewicz A,  Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg 2010;14:1052\u20131061."},{"key":"B25","series-title":"Hepatogastroenterology","first-page":"1750","article-title":"The accuracy of endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, computed tomography, and transabdominal ultrasound in the detection and staging of primary ampullary tumors","volume":"48","author":"Chen CH","year":"2001","unstructured":"Chen CH, Tseng LJ, Yang CC,  The accuracy of endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, computed tomography, and transabdominal ultrasound in the detection and staging of primary ampullary tumors. Hepatogastroenterology 2001;48:1750\u20131753."},{"key":"B26","series-title":"Cancer","first-page":"289","article-title":"Cytologic features and diagnostic pitfalls of primary ampullary tumors by endoscopic ultrasound-guided fine-needle aspiration biopsy","volume":"105","author":"Defrain C","year":"2005","unstructured":"Defrain C, Chang CY, Srikureja W,  Cytologic features and diagnostic pitfalls of primary ampullary tumors by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 2005;105:289\u2013297."},{"key":"B27","series-title":"Oncotarget","first-page":"54526","article-title":"Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection","volume":"7","author":"Gleeson FC","year":"2016","unstructured":"Gleeson FC, Kerr SE, Kipp BR,  Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget 2016;7:54526\u201354536."},{"key":"B28","series-title":"Gastrointest Endosc","first-page":"168","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis","volume":"81","author":"Navaneethan U","year":"2015","unstructured":"Navaneethan U, Njei B, Lourdusamy V,  Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015;81:168\u2013176."},{"key":"B29","series-title":"J Clin Pathol","first-page":"449","article-title":"Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases","volume":"54","author":"Stewart CJ","year":"2001","unstructured":"Stewart CJ, Mills PR, Carter R,  Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J Clin Pathol 2001;54:449\u2013455."},{"key":"B30","series-title":"Gastrointest Endosc","first-page":"456","article-title":"Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis","volume":"97","author":"Kamp EJCA","year":"2023","unstructured":"Kamp EJCA, Dinjens WN, van Velthuysen MF,  Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis. Gastrointest Endosc 2023;97:456\u2013465.e6."},{"key":"B31","series-title":"J Am Coll Surg","first-page":"210","article-title":"Tumors of the ampulla of Vater: histopathologic classification and predictors of survival","volume":"207","author":"Carter JT","year":"2008","unstructured":"Carter JT, Grenert JP, Rubenstein L,  Tumors of the ampulla of Vater: histopathologic classification and predictors of survival. J Am Coll Surg 2008;207:210\u2013218."},{"key":"B32","series-title":"Pancreas","first-page":"990","article-title":"Utility of endoscopic ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies","volume":"47","author":"Larson BK","year":"2018","unstructured":"Larson BK, Tuli R, Jamil LH,  Utility of endoscopic ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies. Pancreas 2018;47:990\u2013995."},{"key":"B33","series-title":"JCO Precis Oncol.","article-title":"Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples","author":"Tomlins SA","unstructured":"Tomlins SA, Hovelson DH, Suga JM,  Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. Published online August 19, 2021. doi:10.1200\/PO.20.00472"},{"key":"B34","series-title":"J Clin Oncol","first-page":"2846","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla M","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM,  Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol 2022;40:2846\u20132857."},{"key":"B35","series-title":"J Clin Med","first-page":"2854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca A","year":"2020","unstructured":"Lamarca A, Kapacee Z, Breeze M,  Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med 2020;9:2854."},{"key":"B36","series-title":"Nat Med","first-page":"1415","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh AR","year":"2019","unstructured":"Parikh AR, Leshchiner I, Elagina L,  Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 2019;25:1415\u20131421."},{"key":"B37","series-title":"Expert Rev Gastroenterol Hepatol","first-page":"471","article-title":"Next generation sequencing for biliary tract cancers","volume":"15","author":"DiPeri TP","year":"2021","unstructured":"DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol 2021;15:471\u2013474."},{"key":"B38","series-title":"J Hepatol","first-page":"170","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca A","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG,  Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 2020;73:170\u2013185."},{"key":"B39","series-title":"Mod Pathol","first-page":"1123","article-title":"Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)","volume":"28","author":"Hechtman JF","year":"2015","unstructured":"Hechtman JF, Liu W, Sadowska J,  Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol 2015;28:1123\u20131129."},{"key":"B40","series-title":"Histopathology","first-page":"236","article-title":"HER-2\/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the Hercep Test","volume":"55","author":"Aloysius MM","year":"2009","unstructured":"Aloysius MM, Lobo DN, Rowlands BJ,  HER-2\/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the Hercep Test. Histopathology 2009;55:236\u2013237."},{"key":"B41","series-title":"Virchows Arch","first-page":"579","article-title":"Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater","volume":"453","author":"Baumhoer D","year":"2008","unstructured":"Baumhoer D, Zlobec I, Tornillo L,  Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Arch 2008;453:579\u2013588."},{"key":"B42","series-title":"Hepatogastroenterology","first-page":"1266","article-title":"Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater","volume":"48","author":"Ajiki T","year":"2001","unstructured":"Ajiki T, Kamigaki T, Hasegawa Y,  Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepatogastroenterology 2001;48:1266\u20131270."},{"key":"B43","series-title":"Lancet Oncol","first-page":"1290","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle M","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS,  Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22:1290\u20131300."},{"key":"B44","series-title":"J Clin Oncol","first-page":"546","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2\/3 amplification (amp), overexpression (oe), or mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"41","author":"Cannon TL","year":"2023","unstructured":"Cannon TL, Rothe M, Garrett-Mayer E,  Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2\/3 amplification (amp), overexpression (oe), or mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 2023;41(Suppl):Abstract 546."},{"key":"B45","series-title":"J Clin Oncol","first-page":"4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba A","year":"2022","unstructured":"Ohba A, Morizane C, Kawamoto Y,  Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol 2022;40(Suppl):Abstract 4006."},{"key":"B46","series-title":"Nat Commun","first-page":"630","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding JJ","year":"2023","unstructured":"Harding JJ, Piha-Paul SA, Shah RH,  Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun 2023;14:630."},{"key":"B47","series-title":"Cancers (Basel)","first-page":"4543","article-title":"Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs","volume":"14","author":"G\u00e1mez-Chiachio M","year":"2022","unstructured":"G\u00e1mez-Chiachio M, Sarri\u00f3 D, Moreno-Bueno G. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers (Basel) 2022;14:4543."},{"key":"B48","series-title":"Surgery","first-page":"260","article-title":"Survival in ampullary cancer: potential role of different KRAS mutations","volume":"157","author":"Valsangkar NP","year":"2015","unstructured":"Valsangkar NP, Ingkakul T, Correa-Gallego C,  Survival in ampullary cancer: potential role of different KRAS mutations. Surgery 2015;157:260\u2013268."},{"key":"B49","series-title":"World J Gastrointest Oncol","first-page":"407","article-title":"Ampullary cancer of intestinal origin and duodenal cancer \u2013 a logical clinical and therapeutic subgroup in periampullary cancer","volume":"9","author":"Chandrasegaram MD","year":"2017","unstructured":"Chandrasegaram MD, Gill AJ, Samra J,  Ampullary cancer of intestinal origin and duodenal cancer \u2013 a logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol 2017;9:407\u2013415."},{"key":"B50","series-title":"Oncotarget","first-page":"58001","article-title":"KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review","volume":"7","author":"Kim BJ","year":"2016","unstructured":"Kim BJ, Jang HJ, Kim JH,  KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget 2016;7:58001\u201358006."},{"key":"B51","series-title":"Lancet Oncol","first-page":"819","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka D","year":"2014","unstructured":"Malka D, Cervera P, Foulon S,  Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014;15:819\u2013828."},{"key":"B52","series-title":"Jpn J Clin Oncol","first-page":"703","article-title":"New developments in systemic therapy for advanced biliary tract cancer","volume":"48","author":"Morizane C","year":"2018","unstructured":"Morizane C, Ueno M, Ikeda M,  New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 2018;48:703\u2013711."},{"key":"B53","series-title":"J Clin Oncol","first-page":"1626","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado RG","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M,  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626\u20131634."},{"key":"B54","series-title":"Oncologist","first-page":"277","article-title":"Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater","volume":"23","author":"Gulhati P","year":"2018","unstructured":"Gulhati P, Raghav K, Shroff R,  Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist 2018;23:277\u2013e26."},{"key":"B55","series-title":"JAMA","first-page":"669","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller LH","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021;325:669\u2013685."},{"key":"B56","series-title":"J Clin Oncol","first-page":"543","article-title":"Efficacy and safety of the MDM2\u2013p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials","volume":"41(","author":"Yamamoto N","year":"2023","unstructured":"Yamamoto N, Tolcher AW, Hafez N,  Efficacy and safety of the MDM2\u2013p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials. J Clin Oncol 2023;41(Suppl):Abstract 543."},{"key":"B57","unstructured":"Tempero MA, Malafa MP, Chiorean EG, et al. NCCN Clinical Practice Guidelines in Oncology: Ampullary Adenocarcinoma. Version 1.2023. Accessed June 8, 2023. To view the most recent, visit https:\/\/www.nccn.org"},{"key":"B58","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B59","series-title":"Histopathology","first-page":"470","article-title":"PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions","volume":"71","author":"Saraggi D","year":"2017","unstructured":"Saraggi D, Galuppini F, Remo A,  PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology 2017;71:470\u2013474."},{"key":"B60","series-title":"J Hematol Oncol Pharm","article-title":"Progression of metastatic, PD-L1\u2013positive, ampullary carcinoma with a treatment holiday from off-label use of pembrolizumab therapy","author":"Heers H","year":"2020","unstructured":"Heers H, Seyedkazemi A, Tanner N,  Progression of metastatic, PD-L1\u2013positive, ampullary carcinoma with a treatment holiday from off-label use of pembrolizumab therapy. J Hematol Oncol Pharm 2020;10:224\u2013227."},{"key":"B61","series-title":"PLoS One","first-page":"e0161438","article-title":"Analysis of founder mutations in rare tumors associated with hereditary breast\/ovarian cancer reveals a novel association of BRCA2 mutations with ampulla of Vater carcinomas","volume":"11","author":"Pinto P","year":"2016","unstructured":"Pinto P, Peixoto A, Santos C,  Analysis of founder mutations in rare tumors associated with hereditary breast\/ovarian cancer reveals a novel association of BRCA2 mutations with ampulla of Vater carcinomas. PLoS One 2016;11:e0161438."},{"key":"B62","series-title":"Pathol Res Pract","first-page":"153309","article-title":"Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer","volume":"217","author":"Kumari N","year":"2021","unstructured":"Kumari N, Singh RK, Mishra SK,  Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. Pathol Res Pract 2021;217:153309."},{"key":"B63","series-title":"Br J Cancer","first-page":"1132","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan T","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R,  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132\u20131138."},{"key":"B64","series-title":"J Clin Oncol","first-page":"1378","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly EM","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M,  Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol 2020;38:1378\u20131388."},{"key":"B65","series-title":"Oncologist","first-page":"1397","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery MA","year":"2011","unstructured":"Lowery MA, Kelsen DP, Stadler ZK,  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397\u20131402."},{"key":"B66","series-title":"J Clin Oncol","first-page":"244","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman B","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK,  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 2015;33:244\u2013250."},{"key":"B67","series-title":"N Engl J Med","first-page":"317","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M,  Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317\u2013327."},{"key":"B68","article-title":"NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2023","author":"Tempero MA","unstructured":"Tempero MA, Malafa MP, Chiorean,  NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2023. Accessed April 28, 2023. To view the most recent, visit https:\/\/www.nccn.org"},{"key":"B69","series-title":"Sci Rep","first-page":"2858","article-title":"Prognostic impact of ATM mutations in patients with metastatic colorectal cancer","volume":"9","author":"Randon G","year":"2019","unstructured":"Randon G, Fuc\u00e0 G, Rossini D,  Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. Sci Rep 2019;9:2858."},{"key":"B70","series-title":"Ann Oncol","first-page":"987","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up","volume":"34","author":"Conroy T","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V,  Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol 2023;34:987\u20131002."},{"key":"B71","series-title":"Lancet Oncol","first-page":"531","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S,  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020;21:531\u2013540."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2D\/article-e237051.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2D\/article-e237051.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2D\/article-e237051.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:49:29Z","timestamp":1718135369000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2D\/article-e237051.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":71,"journal-issue":{"issue":"2D"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7051","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}